Jubilant Pharmova Limited has informed the Exchange about Credit Rating
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
India Ratings and Research has affirmed Jubilant Pharmova Limited's long-term issuer rating at 'IND AA+' with a stable outlook. The agency noted healthy financial performance during FY24 and 9MFY25, supported by improvement in the CDMO Sterile Injectables and Generics businesses. All instrument-level ratings were affirmed, including Rs 150 crore fund-based working capital limits (IND AA+/Stable/IND A1+), Rs 150 crore non-fund-based working capital limits (IND A1+), and Rs 200 crore term loan (IND AA+/Stable). Additionally, an IND A1+ rating was assigned to a proposed Rs 50 crore commercial paper programme, though the instrument has not yet been issued.
The affirmation of the AA+ rating with stable outlook signals strong financial health and creditworthiness, which is positive for shareholders and lenders. It indicates continued confidence in the company's business performance, though the rating action itself is not a change in status, so it is unlikely to cause any major stock price movement.